Form D industry group

Biotechnology

Rounds

1

Latest round

Form D equity offering 2024-04-24

Latest round amount

$240M

Investors

3

People

5

Revenue range

Decline to Discloseas stated on Form D

Website

cidara.com

• Occurred

  May 6, 2024
  Form D filed

  Cidara Therapeutics, Inc. filed Form D: $240,000,000 sold of $240,000,000, Biotechnology

  Form Dobserved 8 days ago
  $240M

Also named here, with no published line of their own (reach them through the firm): Taylor R. Sandison, M.D. (Executive Officer), Leslie R. Tari, PH.D. (Executive Officer), Preetam R. Shah, PH.D. (Executive Officer), Shane R. Ward (Executive Officer), Jeffrey Stein, PH.D. (Executive Officer/Director), Laura R. Tadvalkar, PH.D. (Director), Bonnie R. Bassler, PH.D. (Director), Carin R. Canale-Theakston (Director), Ryan R. Spencer (Director), James R. Merson, PH.D. (Director), Theodore R. Schroeder (Director), Daniel D Burgess (Director).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Graph

Venture Capital

Canonical id

dfx:vc:880601c0-bf39-4a3f-8c04-afda118d131e

First observed

Sep 12, 2026

Last observed

Sep 17, 2026 4 days ago

Resolution

Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.